The 26 references in paper P. Odonchimeg, D. Ichinnorov, Zh. Sarantuyaa, Ts. Tumur-Ochir, G. Choyzhamts, П. Одончимэг, Д. Ичинноров, Ж. Сарантуяа, Ц. Тумур-Очир, Г. Чойжамц (2015) “Эффективность различных форм кортикостероидной терапии у пациентов с обострением хронической обструктивной болезни легких // Efficacy of different regimens of steroid therapy in patients with exacerbation of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2015:i:1:p:58-63

1
Global Strategy for the Diagnosis, Management, and Prevention of COPD. Scientific information and recom\n mendations for COPD programs. Updated 2013. http:// www.goldcopd.org/uploads/users/files/GOLD_Report_2013F eb13.pdf
(check this in PDF content)
2
Soler\nCataluna J.J., Martinez\nGarcia M.A., Roman S.P. et al. Severe acute exacerbations and mortality in patients with COPD. Thorax. 2005; 60: 925–931.
(check this in PDF content)
3
Maltais F., Ostinelli J., Bourbeau J. et al. Comparison of nebulized budesonide and oral predisolone with placebo in the treatment of acute exacerbations of COPD: a random\n ized controlled trial. Am. J. Respir. Crit. Care Med. 2002; 165: 698–703.
(check this in PDF content)
4
Gunen H., Hacievliyagil S.S., Yetkin O. The role of nebi\n lized budesonide in the treatment of exacerbations of COPD.Eur. Respir. J.2007; 29: 660–667.
(check this in PDF content)
5
Henzen C., Suter A., Lerch E. et al. Supression and recov\n ery of adrenal response after short\nterm, high\ndose gluco\n corticoid treatment. Lancet. 2000; 355: 542–545.
(check this in PDF content)
6
Burge P.S., Calverley P.M., Jones P.W. et al. Randomized, double blind, placebo controlled study of fluticasone pro\n pionate in patients with moderate to severe COPD: the ISOLDE trial. Br. Med. J. 2000; 320: 1297–1303.
(check this in PDF content)
7
Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide and formoterol in the management of COPD.Eur. Respir. J.2003; 21: 74–81.
(check this in PDF content)
8
Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in COPD. Eur. Resir. J. 2003; 22: 912–919.
(check this in PDF content)
9
Calverley P.M., Pauwels R., Vestbo J. et al. Combined sal\n meterol and fluticasone in the treatment of COPD: a rando\n mized controlled trial. Lancet.2003; 361 (9356): 449–456.
(check this in PDF content)
10
Calverley P.M., Anderson J.A., Celli B. et al. TORCH inves\n tigators. Salmeterol and fluticasone protionate and survival in COPD.N. Engl. J. Med. 2007; 356: 775–789.
(check this in PDF content)
11
Borg G. Psychophysical bases of perceived exertion. Med. Sci. Sports Exer.1982; 14: 377–381.
(check this in PDF content)
12
Niewoehner D.E., Erbland M.L., Deupree R.H. et al. Effect of systemic glucocorticoids on exacerbations of Chronic Obstructive Pulmonary Disease.N. Engl. J. Med. 1999; 340: 1941–1947.
(check this in PDF content)
13
Davies L., Angus R.M., Calverley P.M.A. Oral corticos\n teroids in patients admitted to hospital with exacerbations of Chronic Obstructive Pulmonary Disease: a prospective ran\n domized controlled trial. Lancet. 1999; 354: 456–460.
(check this in PDF content)
14
Albert R.K., Martin T.R., Lewis S.W. Controlled clinical trial of methylprednisolone in patients with chronic bron\n chitis and acute respiratory failure. Ann. Intern. Med. 1980; 92: 753–758.
(check this in PDF content)
15
Maltais F., Ostinelli J., Bourbeau J. et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial.Am. J. Respir. Crit. Care Med. 2002; 165: 698–703.
(check this in PDF content)
16
Jones P.W., Quirk F.H., Baveystock C.M. The St. George's Respiratory Questionnaire. Respir. Med.1991; 85: 25–31.
(check this in PDF content)
17
Falk J.A., Minai O.A., Mosenifar Z. Inhaled and systemic corticosteroids in Chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2008; 5: 506–512.
(check this in PDF content)
18
Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with COPD. Am. J. Respir. Crit. Care Med.1998; 151: 1418–1422.
(check this in PDF content)
19
Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43–47.
(check this in PDF content)
20
Donaldson G.C., Seemungal T.A.R., Browmik A., Wedzicha J.A. Relationship between exacerbation frequen\n cy and lung function decline in COPD. Thorax. 2002; 57: 847–852.
(check this in PDF content)
21
Seemungal T.A., Donaldson G.C., Browmik A. et al. Time course and recovery of exacerbations in patients with COPD. Am. J. Respir. Crit. Care Med. 2000; 161: 1608–1613.
(check this in PDF content)
22
Rodriguez\nRoisin R. Toward a consensus definition for COPD exacerbation. Chest. 2000; 117: 398–401.
(check this in PDF content)
23
Burge S., Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur. Respir. J. Suppl. 2003; 41: 46S–53S.
(check this in PDF content)
24
Celli B.R., Barnes P.J. Exacerbations of COPD. Eur. Respir. J. 2007; 29: 1224–1238.
(check this in PDF content)
25
Чучалин А.Г. Стандарты диагностики и лечения ХОБЛ. М.: Атмосфера; 2010.
(check this in PDF content)
26
Авдеев С.Н. Карманное руководство для практических врачей.М.: Атмосфера; 2010. Поступила 19.08.14 УДК 616.246036.126085.356
(check this in PDF content)